Tamoxifen debate hinges on whose risk is high enough.

Journal of the National Cancer Institute

Volumn 90, Issue 19, 1998, Pages 1428-1430

  Reynolds, T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PIPERIDINE DERIVATIVE; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST TUMOR; DECISION MAKING; FEMALE; HUMAN; PHYSICIAN ATTITUDE; RISK;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DECISION MAKING; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; PHYSICIAN'S ROLE; PIPERIDINES; RALOXIFENE; RISK; TAMOXIFEN;

EID: 0032494376     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.19.1428     Document Type: Article

References (0)